Klaria Pharma Holding AB (publ.) (KLAR.ST)
SEK 0.29
(-8.63%)
SEK 0.29
(-8.63%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 18.93 Million SEK | 10.81% |
| 2022 | 17.08 Million SEK | -46.14% |
| 2021 | 31.72 Million SEK | 209.14% |
| 2020 | 10.26 Million SEK | -4.73% |
| 2019 | 10.77 Million SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | - SEK | -100.0% |
| 2024 Q2 | - SEK | 0.0% |
| 2023 Q1 | - SEK | -100.0% |
| 2023 Q2 | - SEK | 0.0% |
| 2023 Q3 | - SEK | 0.0% |
| 2023 Q4 | 18.93 Million SEK | 0.0% |
| 2023 FY | 18.93 Million SEK | 10.81% |
| 2022 Q3 | 848 Thousand SEK | 0.0% |
| 2022 FY | 17.08 Million SEK | -46.14% |
| 2022 Q2 | 848 Thousand SEK | 0.0% |
| 2022 Q1 | 848 Thousand SEK | -97.33% |
| 2022 Q4 | 17.08 Million SEK | 1914.74% |
| 2021 Q3 | - SEK | 0.0% |
| 2021 Q2 | - SEK | 0.0% |
| 2021 FY | 31.72 Million SEK | 209.14% |
| 2021 Q1 | - SEK | -100.0% |
| 2021 Q4 | 31.72 Million SEK | 0.0% |
| 2020 Q2 | 130 Thousand SEK | 0.0% |
| 2020 FY | 10.26 Million SEK | -4.73% |
| 2020 Q4 | 10.26 Million SEK | 7793.85% |
| 2020 Q1 | 130 Thousand SEK | -98.79% |
| 2020 Q3 | 130 Thousand SEK | 0.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2019 Q2 | - SEK | 0.0% |
| 2019 Q1 | - SEK | 0.0% |
| 2019 FY | 10.77 Million SEK | 0.0% |
| 2019 Q4 | 10.77 Million SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AcuCort AB | - SEK | -Infinity% |
| AlzeCure Pharma AB (publ) | - SEK | -Infinity% |
| BioGaia AB (publ) | 8.8 Million SEK | -115.136% |
| Enzymatica AB (publ) | 26.1 Million SEK | 27.472% |
| Enorama Pharma AB (publ) | 436 Thousand SEK | -4242.202% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Moberg Pharma AB (publ) | 4.73 Million SEK | -299.662% |
| Nanexa AB (publ) | 4.03 Million SEK | -369.544% |
| Newbury Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| ODI Pharma AB | - SEK | -Infinity% |
| Orexo AB (publ) | 473.8 Million SEK | 96.004% |
| Probi AB (publ) | 53.79 Million SEK | 64.808% |
| Swedencare AB (publ) | 1.65 Billion SEK | 98.859% |
| Swedish Orphan Biovitrum AB (publ) | 20.48 Billion SEK | 99.908% |
| Toleranzia AB | 850 Thousand SEK | -2127.294% |
| Vivesto AB | 8.16 Million SEK | -131.783% |